A look at what to expect when companies report third-quarter 2025 operating results beginning in late October and extending through November.

This month I share insights into how I might temporarily downsize or exit Finch Trades positions if the market keeps melting up.

A look at what to expect when companies report second-quarter 2025 operating results beginning in late July and extending through August.

A look at what to expect when companies report first-quarter 2025 operating results beginning in late April and extending through May.

This month I explain why tariffs have minimal impact on drug developers, revisit timely advice from legendary investor Joel Greenblatt, and share an updated goal for my position in Relay Therapeutics.

This month I reveal my lessons from the last market bubble and correction, which influences my current strategy. I also beat you over the head as a reminder to avoid FOMO, remain disciplined, and keep your emotions separated from your money.

This month we dive into the topic of leveraging data readouts to raise money while limiting dilution. Investors may get a real-world demonstration this week following a data readout for RLY-2608.

This month's summary of recent events, upcoming events, and exploring a biotech investing topic. This month we discuss the good, the bad, and the ugly of stock-based compensation.

This month introduces the Member Digest, our new summary of recent events, upcoming events, and exploring a biotech investing topic. This month we rank the acquisition potential of each company in the coverage ecosystem.

The finch is getting rid of the Flyers category and replacing two companies in the biotech stocks we cover.

Quick updates for Coherus BioSciences, Exact Sciences, Krystal Biotech, and Selecta Biosciences.